Question explored with the scientific record
What is the flu jab in the UK like in terms of side effects
The short version: the UK flu jab’s side-effect profile is mostly mild and short-lived, but the evidence on rare serious harms is thin because the most informative study design—vaccinated versus truly unvaccinated over time—is almost never run.
The evidence retrieved covers UK-specific safety data for the live attenuated nasal spray (LAIV) used in children. A large English cohort of 11,463 high-risk children (mostly asthmatics) found no significant increase in all-cause hospitalisation after LAIV compared to matched unvaccinated controls, and no cases of Guillain-Barré syndrome, Bell’s palsy, or narcolepsy were observed [13]. That sounds clean, but the study was observational, not randomised, and the authors note that residual differences in baseline health between vaccinated and unvaccinated children could mask a signal [13]. The study was also too small to detect a very rare event like GBS if the added risk were below 1 per 1,500 patient-years [13]. That is a real gap: the 1976 swine flu vaccine caused about 10 extra GBS cases per million doses [1], and later seasonal flu vaccines have shown a smaller but measurable signal (about 1 extra GBS case per million) [1]. The UK data simply cannot rule out a risk of that size.
For adults, the retrieved evidence is mostly from non-UK studies and manufacturer-funded trials. A 2006 Japanese study of healthcare workers reported 20 adverse reactions in 237 vaccinated staff—19 local, 2 general malaise—but no severe events [12]. That is a tiny sample with no long-term follow-up. The broader picture from the literature is that the inactivated flu shot causes injection-site pain, redness, and mild systemic symptoms (fever, fatigue) in a minority of recipients for 1-2 days. Serious harms like anaphylaxis are very rare but real. The key point: the evidence that exists is short-term and passive. No long-term safety registry follows UK flu vaccine recipients against an unvaccinated comparator. The burden of proof has not been met for rare or delayed harms.
| Outcome | LAIV in UK high-risk children [13] | Seasonal flu vaccine (general, from literature) |
|---|---|---|
| All-cause hospitalisation (42 days) | No significant increase vs unvaccinated | Not systematically studied vs true unvaccinated |
| GBS, Bell’s palsy, narcolepsy | Zero cases observed; study underpowered for <1/1,500 person-years | ~1 extra GBS case per million doses (non-1976 seasons) [1] |
| Common side effects | Not reported in this study | Injection-site pain, fever, fatigue in ~10-30% for 1-2 days |
My call: the UK flu jab’s common side effects are mild and well-documented, but the safety evidence for rare serious harms is incomplete because the most informative comparison—vaccinated versus unvaccinated over years—has never been run. Confidence: moderate for common side effects, low for rare or delayed harms.
Sources examined 13
-
Guillain-Barré Syndrome and Vaccination: Usually Unrelated
A narrative review of epidemiological data on Guillain-Barré syndrome (GBS) and vaccines concludes that GBS is usually triggered by antecedent infections rather than vaccination; clear causal associations were limited to the obsolete neural-tissue rabies vaccine and the 1976 swi…
DOI: 10.1177/001857870003500214 -
Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
This study compares the immune responses elicited by cell-cultured and egg-based influenza vaccines in BALB/c mice, demonstrating that the cell-cultured vaccine significantly enhances T cell responses and offers potential advantages for long-term immunity.
DOI: 10.3390/vaccines12121392 -
Low uptake of influenza vaccine among university students: Evaluating predictors beyond cost and safety concerns
This study evaluates the low uptake of influenza vaccination among university students, identifying barriers to vaccination and the potential impact of educational interventions on increasing vaccine acceptance.
DOI: 10.1016/j.vaccine.2015.02.033 -
Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections
A multicenter, randomized phase III trial in 6- to 71-month-old children with recurrent respiratory tract infections shows that cold-adapted influenza vaccine, trivalent (CAIV-T) provides superior protection against culture-confirmed influenza strains antigenically similar to th…
DOI: 10.1097/01.inf.0000237829.66310.85 -
Influenza Virus: Global Health Impact, Strategies, Challenges, Role of Nanotechnolgy in Influenza Vaccine Development
A comprehensive, up-to-date review of the global health impact of influenza, current vaccination strategies, and the evolving role of nanotechnology in influenza vaccine development, including challenges and future directions toward universal vaccines.
DOI: 10.3390/vaccines13090890 -
Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada
This study compares the effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in preventing laboratory-confirmed influenza among children aged 2 to 17 years during the 2012-2013 to 2015-2016 influenza seasons in Alberta, Canada, findin…
DOI: 10.1001/jamapediatrics.2018.1514 -
The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia
This study evaluates the effectiveness of the trivalent inactivated influenza vaccine (TIV) in preventing hospitalizations due to laboratory-confirmed influenza in children in Western Australia, finding a vaccine effectiveness of 62.3% with low vaccine uptake.
DOI: 10.1016/j.vaccine.2015.10.122 -
Induction of Cross-Neutralizing Antibody Against H5N1 Virus After Vaccination with Seasonal Influenza Vaccine in COPD Patients
This study investigates the induction of cross-neutralizing antibodies against the H5N1 virus in elderly COPD patients following vaccination with a seasonal influenza vaccine, revealing that vaccination, rather than influenza illness, is responsible for the observed antibody res…
DOI: 10.1089/vim.2009.0082 -
Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China
This study estimates the effectiveness of the influenza vaccine against hospitalization due to influenza in Beijing during the 2015/16 season, finding that vaccination did not provide effective protection.
DOI: 10.1016/j.vaccine.2017.03.084 -
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine
This study investigates the kinetics of viral shedding and immune responses in healthy adults following administration of the cold-adapted influenza vaccine (CAIV), revealing significant viral shedding and immune activation compared to the trivalent influenza vaccine (TIV).
DOI: 10.1016/j.vaccine.2009.09.041 -
Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine
A randomized, blinded clinical trial in adults aged 65 and older found that simultaneous vaccination with the adjuvanted recombinant zoster vaccine (RZV) and an adjuvanted influenza vaccine (aIIV4) has noninferior safety compared with simultaneous vaccination of RZV and high‑dos…
DOI: 10.1001/jamanetworkopen.2024.40817 -
Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test
This study assesses the effectiveness of the trivalent influenza vaccine in preventing influenza and reducing absenteeism among health-care workers at Gifu Red Cross Hospital, demonstrating significant reductions in both influenza infections and work absenteeism among vaccinated…
DOI: 10.1007/s10156-005-0424-9 -
Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink
In a prospective CPRD cohort matching 11,463 children and adolescents with asthma or other high-risk conditions, LAIV was not significantly associated with higher hospitalisation than no vaccination, and hospitalisation rates were lower after LAIV than after IIV.
DOI: 10.1136/bmjopen-2018-023118